NASDAQ: TCRX
Tscan Therapeutics Inc Stock Ownership - Who owns Tscan Therapeutics?

Insider buying vs selling

Have Tscan Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Lynx1 Capital Management LP10% Owner2024-12-13100,000$2.90
$290.10kBuy
Lynx1 Capital Management LP10% Owner2024-12-1231,800$3.01
$95.62kBuy
Lynx1 Capital Management LP10% Owner2024-11-15947$4.34
$4.11kBuy
Barbara KlenckeDirector2024-09-235,000$5.29
$26.45kBuy
Barbara KlenckeDirector2024-08-265,000$5.53
$27.65kBuy
Barbara KlenckeDirector2024-08-235,000$5.69
$28.45kBuy
Zoran ZdraveskiChief Legal and Strategy Officer2024-08-2354,895$4.85
$266.24kBuy
Zoran ZdraveskiChief Legal and Strategy Officer2024-08-23164,686$5.78
$952.05kSell
Zoran ZdraveskiChief Legal and Strategy Officer2024-08-2364,166$2.49
$159.77kBuy
Zoran ZdraveskiChief Legal and Strategy Officer2024-08-2313,125$1.81
$23.76kBuy

1 of 2

TCRX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when TCRX insiders and whales buy or sell their stock.

TCRX Shareholders

What type of owners hold Tscan Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Lynx1 Capital Management LP9.47%5,357,347$7.71MInstitution
Lynx1 Capital Management LP9.47%5,357,347$7.71MInsider
Ecor1 Capital LLC8.84%5,000,000$7.20MInsider
Ecor1 Capital LLC8.84%5,000,000$7.20MInstitution
Blackrock Inc8.77%4,961,700$7.14MInstitution
Adage Capital Partners GP LLC6.18%3,500,000$5.04MInstitution
Bvf Inc5.28%2,989,474$4.30MInstitution
Baker Bros Advisors LP4.92%2,784,792$4.01MInstitution
Baker Bros Advisors LP4.47%2,528,583$3.64MInsider
Vanguard Group Inc4.21%2,382,533$3.43MInstitution

1 of 3

TCRX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
TCRX73.39%25.38%Net Buying
ANIX17.68%82.32%Net BuyingNet Buying
KYTX56.40%43.60%Net Buying
VOR48.80%36.98%Net SellingNet Selling
EXOZ0.72%99.28%Net Buying

Tscan Therapeutics Stock Ownership FAQ

Who owns Tscan Therapeutics?

Tscan Therapeutics (NASDAQ: TCRX) is owned by 73.39% institutional shareholders, 25.38% Tscan Therapeutics insiders, and 1.23% retail investors. Lynx1 Capital Management LP is the largest individual Tscan Therapeutics shareholder, owning 5.36M shares representing 9.47% of the company. Lynx1 Capital Management LP's Tscan Therapeutics shares are currently valued at $8.20M.

If you're new to stock investing, here's how to buy Tscan Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.